Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.67 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29729259 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2MEN1CYP3A4 | |
| SCHEMBL30920079 | 0.87 | TSHR (0.77) | ALDH1A1MAPTSMN1; SMN2MEN1CYP3A4 | |
| SCHEMBL21227017 | 0.87 | TSHR (0.77) | ALDH1A1MAPTSMN1; SMN2MEN1CYP3A4 | |
| SCHEMBL17986849 | 0.86 | ALDH1A1 (0.76) | ALDH1A1MAPTSMN1; SMN2MEN1CYP3A4 | |
| SCHEMBL21045079 | 0.85 | MAPT (0.74) | ALDH1A1MAPTSMN1; SMN2MEN1CYP3A4 | |
| SCHEMBL29411505 | 0.85 | MAPT (0.74) | ALDH1A1MAPTSMN1; SMN2MEN1CYP3A4 | |
| SCHEMBL24968055 | 0.84 | MAPT (0.72) | ALDH1A1MAPTSMN1; SMN2MEN1CYP3A4 | |
| SCHEMBL20508328 | 0.84 | ALDH1A1 (0.72) | ALDH1A1MAPTSMN1; SMN2MEN1CYP3A4 | |
| SCHEMBL31315992 | 0.84 | ALDH1A1 (0.72) | ALDH1A1MAPTSMN1; SMN2MEN1CYP3A4 | |
| SCHEMBL21045479 | 0.84 | ALDH1A1 (0.72) | ALDH1A1MAPTSMN1; SMN2MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | Poolbeg Pharma (UK) Limited (GB) | 2024-11-19 | — | — | US | claimed |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-05-24 | — | — | US | claimed |
| US-20080207519-A1 | Inhibition of Hsp27 Phosphorylation for the Treatment of Blistering Disorders | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2008-08-28 | — | — | US | claimed |
| EP-1824336-A2 | INHIBITION OF HSP27 PHOSPHORYLATION FOR TREATMENT OF BLISTERING DISORDERS | The University of North Carolina at Chapel Hill (US) | 2007-08-29 | — | — | EP | claimed |
| WO-2006071456-A2 | INHIBITION OF HSP27 PHOSPHORYLATION FOR TREATMENT OF BLISTERING DISORDERS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2006-07-06 | — | — | WO | claimed |
| US-20260115177-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERA-PY-ASSOCIATED CYTOKINE RELEASE SYNDROME | POOLBEG PHARMA UK LTD (GB) | 2026-04-30 | — | — | US | disclosed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250188035-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE LLC (US) | 2025-06-12 | — | — | US | disclosed |
| US-12247010-B2 | Tubulin inhibitors | LIN BIOSCIENCE INC. (TW) | 2025-03-11 | — | — | US | disclosed |
| EP-4484952-A2 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | The Regents of the University of California (US) | 2025-01-01 | — | — | EP | disclosed |
| EP-3661539-B1 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | UNIV CALIFORNIA (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240207422-A1 | NERVE TARGETING PEPTIDE CONJUGATES AND METHODS OF USE | ALUME BIOSCIENCES INC (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2011008992-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011008996-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2010121023-A2 | PEPTIDES AND APTAMERS FOR TARGETING OF NEURON OR NERVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010008995-A2 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016218-A1 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20080207519-A1 | Inhibition of Hsp27 Phosphorylation for the Treatment of Blistering Disorders | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2008-08-28 | — | — | US | disclosed |
| EP-1824336-A2 | INHIBITION OF HSP27 PHOSPHORYLATION FOR TREATMENT OF BLISTERING DISORDERS | The University of North Carolina at Chapel Hill (US) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006071456-A2 | INHIBITION OF HSP27 PHOSPHORYLATION FOR TREATMENT OF BLISTERING DISORDERS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016218-A1 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | BAX, BCL2, AIFM1 | ALDH1A1 2701/4885MAPT 3300/4885SMN1; SMN2 2221/4885 |
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, CCL11 | ALDH1A1 2539/4885MAPT 3797/4885SMN1; SMN2 4777/4885 |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | ALDH1A1 4784/4885MAPT 832/4885SMN1; SMN2 343/4885 |
| US-12247010-B2 | Tubulin inhibitors | TUBB3, TUBB1, TUBB | ALDH1A1 3048/4885MAPT 24/4885SMN1; SMN2 1062/4885 |
| US-20250188035-A1 | TUBULIN INHIBITORS | TUBB3, TUBB1, TUBB | ALDH1A1 3048/4885MAPT 24/4885SMN1; SMN2 1062/4885 |
| US-20260115177-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERA-PY-ASSOCIATED CYTOKINE RELEASE SYNDROME | MAPK13, MAPK11, MAPK1 | ALDH1A1 4407/4885MAPT 835/4885SMN1; SMN2 2341/4885 |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, MAPK1 | ALDH1A1 2627/4885MAPT 3752/4885SMN1; SMN2 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.